In this edition, DNA sequencing could identify patients with high-risk AML; review of major advances and challenges in chronic lymphocytic leukemia; FDA advisory panel backs polatuzumab vedotin and more. Read the full coverage here:

DNA sequencing could identify patients with AML at high risk for relapse after HSCT

Review highlights major advances, continuing challenges in chronic lymphocytic leukemia

FDA advisory panel backs polatuzumab vedotin-piiq benefit-risk profile in first-line DLBCL

CAR T cells improve quality of life for majority of recipients

Community physicians play essential role in long-term care after CAR-T

References:

Dillon LW, et al. JAMA. 2023;doi:10.1001/jama.2023.1363.

Healio Interviews

Johnson PC, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2022009117.

March 9, 2023 meeting of the Oncologic Drugs Advisory Committee (ODAC). Available at: https://www.youtube.com/watch?v=zCf87ABhqpU. Accessed March 9, 2023.

Shadman M. JAMA. 2023;doi:10.1001/jama.2023.1946.